NCT07803588 A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)
| NCT ID | NCT07803588 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AdaptDx, Inc. |
| Condition | Healthy Adult Participants |
| Study Type | OBSERVATIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-09-15 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 24 participants in total. It began in 2026-09-15 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.
Eligibility Criteria
Inclusion Criteria: Subjects enrolled in the study will be required to meet all the following criteria for both eyes: 1. Male or female between the ages of 22 and 49 (inclusive) at Visit 1 2. ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1 3. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study 4. Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines Exclusion Criteria: 1. Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes 2. Diagnosis or history of any ocular disease or disorder 3. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study 4. Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ 5. Is non-ambulatory 6. History of drug, alcohol or substance abuse within 3 months prior to Visit 1 7. Has received an investigational drug or treatment with an investigational device within 3 months prior to Visit 1 8. In the opinion of the Investigator, is unlikely to comply with the study protocol
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07803588 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 49 Years, studying Healthy Adult Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07803588 currently recruiting?
Yes, NCT07803588 is actively recruiting participants. Contact the research team at ccroissant@opzira.com for enrollment information.
Where is the NCT07803588 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT07803588 clinical trial?
NCT07803588 is sponsored by AdaptDx, Inc.. The trial plans to enroll 24 participants.